ALDER BIOPHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $683,000 | $113,000 | — | $4.8M | $4.6M |
| Operating income | −$286.6M | −$291.0M | −$157.9M | −$86.3M | $8.8M | −$20.8M |
| Net income | −$296.4M | −$288.9M | −$156.3M | −$85.5M | $8.9M | −$20.6M |
| Total assets | $426.2M | $303.1M | $409.2M | $400.0M | $64.4M | $26.7M |
| Total liabilities | $212.5M | $23.9M | $26.4M | $12.5M | $5.2M | $58.7M |
| Equity | $110.0M | $279.3M | $382.8M | $387.5M | $59.2M | −$143.4M |
| EPS (diluted) | — | — | $-3.23 | $-2.11 | $0.30 | $-21.14 |
| Shares out. | 67.8M | 50.4M | 43.8M | 37.9M | 31.0M | 988,685 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- —
- Net margin
- —
- Return on equity
- −269.5%
- Return on assets
- −69.5%
- Return on capital (ROCE)
- −72.0%
- Liabilities / assets
- 49.9%
- Debt / equity
- 1.93×
- Book value / share
- $1.62
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -5.32distress
- Accruals / assets
- −10.7%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 22, 2019
- Entered a material agreement · Amended charter or bylaws · Other material eventSep 16, 2019
- Results of operationsAug 6, 2019
- Shareholder voteMay 24, 2019
- Other material eventMay 2, 2019
- Results of operationsMay 2, 2019
- Director / officer changeApr 12, 2019
- Director / officer changeMar 28, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AAMENDMENT TO FORM SC 13GFeb 13, 2020
- 15-12BNov 1, 2019
- SC 13GALDER BIOPHARMACEUTICALS, INC.Oct 31, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4OWNERSHIP DOCUMENTOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
- 4FORM 4 SUBMISSIONOct 24, 2019
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.